case_images: PMC9500430_01
case_images: Positron emission tomography/computed tomography imaging. Positron emission tomography/computed tomography imaging on 19 February 2019 revealed an enlarged nodule measuring 1.4 cm x 1.5 cm on let upper lobe (LLL) with a maximum standardized uptake value (SUVmax) of 8.6, right cervical lymph nodes at 0.9 cm x 1.0 cm with SUVmax 8.8.
case_images: fphar-13-898623-g001.jpg
case_images: PMC9500430_01_fphar-13-898623-g001.jpg
case_images: F1
case_images: The patient was clinically diagnosed as stage IV-T1bN3M1 with an Eastern Cooperative Oncology Group performance score of 1 at initial diagnosis (Figure 1).
case_images: Response evaluation. (A) Radiographic response evaluation; (B) Change in carcinoembryonic antigen.
case_images: fphar-13-898623-g002.jpg
case_images: PMC9500430_01_fphar-13-898623-g002.jpg
case_images: F2
case_images: A partial response, including a 60.2% reduction in the primary target lesion and 74.7% reduction in the metastatic lymph nodes, was observed on the first computed tomography scan evaluation after two cycles of treatment with pembrolizumab combined with carboplatin/pemetrexed (Figure 2A). In addition, carcinoembryonic antigen levels decreased to the normal range (0-5 ng/ml) (Figure 2B).